Premium
Intrathecal n, n′, n′‐triethylenethiophosphoramide [thio‐tepa (NSC 6396)] in the treatment of malignant meningeal disease. Phase I‐II study
Author(s) -
Gutin Philip H.,
Weiss Howard D.,
Wiernik Peter H.,
Walker Michael D.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197610)38:4<1471::aid-cncr2820380404>3.0.co;2-0
Subject(s) - medicine , intrathecal , toxicity , thio , lumbar , dose , gastroenterology , surgery , chemistry , stereochemistry
N, N′, N″‐Triethylenethiophosphoramide [Thio‐TEPA (NSC 6396)] is the third drug to be evaluated for the treatment of meningeal neoplasia. Eleven patients with meningeal leukemia, lymphoma, or ependymoma were treated with intrathecal thio‐TEPA in doses from 1 to 10 mg/m 2 of body surface area. There was no hematologic toxicity definitely attributable to thio‐TEPA, and neurologic toxicity was limited to mild transient paresthesias of the lower extremities during lumbar sac injection in three patients. Two of those experiencing such paresthesias received concentrated drug solutions to decrease the large injected volumes associated with the higher dosages of thio‐TEPA. Three patients achieved complete meningeal remission, and five others had a partial response to therapy.